Cargando…

Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

BACKGROUND: Recently, immune checkpoint inhibitors have shown survival advantage over chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). This meta-analysis was conducted to gather and analyze the available evidence (Evidence level I; Randomized Controlled Trials) comparing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Muhammad, Lin, Jie, Liao, Guixiang, Tian, Yunhong, Liang, Yingying, Li, Rong, Liu, Mengzhong, Yuan, Yawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113026/ https://www.ncbi.nlm.nih.gov/pubmed/30113497 http://dx.doi.org/10.1097/MD.0000000000011936

Ejemplares similares

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases
por: Khan, Muhammad, et al.
Publicado: (2018)

Whole Brain Radiation Therapy Plus Stereotactic Radiosurgery in the Treatment of Brain Metastases Leading to Improved Survival in Patients With Favorable Prognostic Factors
por: Khan, Muhammad, et al.
Publicado: (2019)

Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases
por: Khan, Muhammad, et al.
Publicado: (2020)

Comparative analysis of robotic gastrectomy and laparoscopic gastrectomy for gastric cancer in terms of their long-term oncological outcomes: a meta-analysis of 3410 gastric cancer patients
por: Liao, Guixiang, et al.
Publicado: (2019)

PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2023)

Case report: Brain metastasis necrosis with immune checkpoint inhibitors plus chemotherapy for advanced non-small cell lung cancer
por: Niu, Lishui, et al.
Publicado: (2022)

Long noncoding RNA LINC02582 acts downstream of miR-200c to promote radioresistance through CHK1 in breast cancer cells
por: Wang, Baiyao, et al.
Publicado: (2019)

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
por: Kuo, Chih‐Hsi Scott, et al.
Publicado: (2019)

Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis
por: Cao, Rui, et al.
Publicado: (2019)

Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?
por: Kanwal, Bushra, et al.
Publicado: (2018)

Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis
por: Alifu, Muyesar, et al.
Publicado: (2023)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: Ma, Yue, et al.
Publicado: (2022)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
por: Wang, Chengdi, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Ji, Qiao, et al.
Publicado: (2021)

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Huang, Zhe, et al.
Publicado: (2023)

Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials
por: Li, Jie, et al.
Publicado: (2019)

Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review
por: Lin, Chen, et al.
Publicado: (2023)

Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis
por: Khan, Muhammad, et al.
Publicado: (2021)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis
por: Qiu, Lupeng, et al.
Publicado: (2022)

A Complete Sustained Response of Advanced Non-Small-Cell Lung Cancer After Immune Checkpoint Inhibitor, Radiotherapy, and Chemotherapy
por: Vilas-Boas, Isabel, et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world
por: Shi, Yue, et al.
Publicado: (2022)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

Pooled analysis of the clinical benefit of cyclooxygenase-2 inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Zheng, Wei, et al.
Publicado: (2019)

Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
por: Tun, Aung Myint, et al.
Publicado: (2019)

Neoadjuvant immune checkpoint inhibitor treatment + chemotherapy (vs. chemotherapy alone) for locally advanced non‑small cell lung cancer: A retrospective cohort study
por: Yang, Yi, et al.
Publicado: (2023)

Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy
por: Wu, Di, et al.
Publicado: (2017)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

Immune checkpoint inhibitors for first‐line treatment of advanced non‐small‐cell lung cancer: A systematic review and network meta‐analysis
por: Peng, Tzu‐Rong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy
por: Riemann, Dagmar, et al.
Publicado: (2023)

Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis
por: Li, Xin, et al.
Publicado: (2017)

Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
por: Addeo, Alfredo, et al.
Publicado: (2019)

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
por: Zeng, Hao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3vqjk0kis7tq8kngn1d5qc5v51